Physician profile
Daniel P Tveit
NPI 1942207162
$6,928.40
in general payments reported to CMS, 2019-2025
28 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $682 · 2021: $933 · 2022: $1,080 · 2023: $1,119 · 2024: $1,358 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403 · Education: $89.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.28 |
| Education | $89.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $988.17 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals Lp | $758.82 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $689.56 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $677.47 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $629.29 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $489.41 | 2020-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $416.94 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $416.91 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $396.05 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $257.67 | 2022-2025 | |
| Travere Therapeutics, INC. | $179.60 | 2022-2024 | |
| Novo Nordisk INC | $152.65 | 2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $113.25 | 2024-2025 | |
| Ardelyx, INC. | $99.04 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $95.15 | 2019-2023 | Ultomiris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $77.41 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $71.40 | 2021-2023 | Benlysta |
| Daiichi Sankyo INC. | $64.26 | 2020-2024 | Injectafer |
| Cormedix INC. | $64.17 | 2024 | Defencath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.26 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $52.99 | 2022-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $47.06 | 2019 | |
| Lilly USA, LLC | $34.91 | 2024-2025 | Jardiance |
| Shire North American Group INC | $25.35 | 2019 | |
| Scpharmaceuticals INC. | $18.90 | 2025 | |
| Apellis Pharmaceuticals, INC. | $18.57 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.60 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tveit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.